COLLEEN PAPENHAUSEN: Open Payments
NPI 1396166161 · ALLENTOWN, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,789 in 68 payments from 18 companies in 2025. Trend: 2023 $774 · 2024 $890 · 2025 $1,789
Food & beverage: $1,705Education: $84
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 10 | $329 |
| Janssen Biotech, Inc. | 8 | $217 |
| Ardelyx, Inc. | 7 | $199 |
| ABBVIE INC. | 9 | $193 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $123 |
| GENZYME CORPORATION | 1 | $120 |
| Aimmune Therapeutics, Inc. | 3 | $68 |
| Exact Sciences Corporation | 2 | $55 |
| Ferring Pharmaceuticals Inc. | 2 | $47 |
Products named: REZDIFFRA, TREMFYA, IBSRELA, DUPIXENT, XIFAXAN, ENTYVIO, RINVOQ, ZENPEP.
Industry payments across PA — which companies pay providers there.
